Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

"Not only did we meet our prespecified safety and efficacy endpoint, we also saw excellent valve hemodynamics and valve function, and there was a very low rate ... with aortic stenosis, a type ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

The Evolut Low Risk Trial was a randomized ... and durable alternative to surgery for patients with severe aortic stenosis, regardless of their surgical risk," said Michael J.